CoChat

Mast cells and metabolic syndrome

Open access
Zhang, Jie, Shi, Guo-Ping · 2012 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Cited by 104

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Mast cells are critical effectors in the development of allergic diseases and in many immunoglobulin E–mediated immune responses. These cells exert their physiological and pathological activities by releasing granules containing histamine, cytokines, chemokines, and proteases, including mast cell-specific chymase and tryptase. Like macrophages and T lymphocytes, mast cells are inflammatory cells, and they participate in the pathogenesis of inflammatory diseases such as cardiovascular complications and metabolic disorders. Recent observations suggested that mast cells are involved in insulin resistance and type 2 diabetes. Data from animal models proved the direct participation of mast cells in diet-induced obesity and diabetes. Although the mechanisms by which mast cells participate in these metabolic diseases are not fully understood, established mast cell pathobiology in cardiovascular diseases and effective mast cell inhibitor medications used in pre-formed obesity and diabetes in experimental models offer hope to patients with these common chronic inflammatory diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbadis.2010.12.012

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 88

  1. von Recklinghausen, 1863, Ueber eiter- und bindegewebskörperchen, Virchows Arch, 28, 157, 10.1007/BF01930779 · DOI
  2. Waldeyer, 1875, Ueber Bindegewebeszellen, Arch Mikrosk Anat, 11, 176, 10.1007/BF02933794 · doi:10.1007/bf02933794
  3. Ehrlich, 1877, Beitr kenntniss anilinfarbungen verwendung mikroskopischen technik, 13, 263
  4. Kitamura, 1977, Development of mast cells from grafted bone marrow cells in irradiated mice, Nature, 268, 442, 10.1038/268442a0 · DOI · Paper page
  5. Nabel, 1981, Inducer T lymphocytes synthesize a factor that stimulates proliferation of cloned mast cells, Nature, 291, 332, 10.1038/291332a0 · DOI · Paper page
  6. Metcalfe, 1997, Mast cells, Physiol Rev, 77, 1033, 10.1152/physrev.1997.77.4.1033 · DOI · Paper page
  7. Kawakami, 2002, Regulation of mast-cell and basophil function and survival by IgE, Nat Rev Immunol, 2, 773, 10.1038/nri914 · DOI · Paper page
  8. Galli, 1994, The kit ligand, stem cell factor, Adv Immunol, 55, 1, 10.1016/S0065-2776(08)60508-8 · DOI · Paper page
  9. Kitamura, 1989, Heterogeneity of mast cells and phenotypic change between subpopulations, Annu Rev Immunol, 7, 59, 10.1146/annurev.iy.07.040189.000423 · doi:10.1146/annurev.iy.07.040189.000423 · Paper page
  10. Dvorak, 1991, Basophil and mast cell degranulation and recovery, vol. 4
  11. Dvorak, 1992, Basophils and mast cells: piecemeal degranulation in situ and ex vivo: a possible mechanism for cytokine-induced function in disease, Immunol Ser, 57, 169
  12. Krishnaswamy, 2006, The human mast cell: an overview, Meth Mol Biol, 315, 13
  13. Ventre, 1997, Targeted disruption of the tumor necrosis factor-alpha gene: metabolic consequences in obese and nonobese mice, Diabetes, 46, 1526, 10.2337/diab.46.9.1526 · DOI · Paper page
  14. Pejler, 2007, Mast cell proteases, Adv Immunol, 95, 167, 10.1016/S0065-2776(07)95006-3 · DOI · Paper page
  15. Okumura, 2003, Identification of specific gene expression profiles in human mast cells mediated by Toll-like receptor 4 and FcepsilonRI, Blood, 102, 2547, 10.1182/blood-2002-12-3929 · DOI · Paper page
  16. Metzger, 1992, The receptor with high affinity for IgE, Immunol Rev, 125, 37, 10.1111/j.1600-065X.1992.tb00624.x · DOI · Paper page
  17. Marshall, 2004, Mast-cell responses to pathogens, Nat Rev Immunol, 4, 787, 10.1038/nri1460 · DOI · Paper page
  18. Grimbaldeston, 2007, Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B, Nat Immunol, 8, 1095, 10.1038/ni1503 · DOI · Paper page
  19. Kitamura, 1978, Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation, Blood, 52, 447, 10.1182/blood.V52.2.447.447 · DOI · Paper page
  20. Lyon, 1982, A new allele sash (Wsh) at the W-locus and a spontaneous recessive lethal in mice, Genet Res, 39, 315, 10.1017/S001667230002098X · DOI · Paper page
  21. Berrozpe, 1999, The W(sh), W(57), and Ph Kit expression mutations define tissue-specific control elements located between -23 and -154kb upstream of Kit, Blood, 94, 2658, 10.1182/blood.V94.8.2658.420k23_2658_2666 · DOI · Paper page
  22. Duttlinger, 1993, W-sash affects positive and negative elements controlling c-kit expression: ectopic c-kit expression at sites of kit-ligand expression affects melanogenesis, Development, 118, 705, 10.1242/dev.118.3.705 · DOI · Paper page
  23. Wolters, 2005, Tissue-selective mast cell reconstitution and differential lung gene expression in mast cell-deficient Kit(W-sh)/Kit(W-sh) sash mice, Clin Exp Allergy, 35, 82, 10.1111/j.1365-2222.2005.02136.x · DOI · Paper page
  24. Sun, 2007, Mast cells promote atherosclerosis by releasing proinflammatory cytokines, Nat Med, 13, 719, 10.1038/nm1601 · DOI · Paper page
  25. Ebmeyer, 2010, Reconstitution of the mast cell population in W/Wv mice, Otol Neurotol, 31, 42, 10.1097/MAO.0b013e3181b4e3e3 · DOI
  26. Galli, 2008, Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis, J Dermatol Sci, 49, 7, 10.1016/j.jdermsci.2007.09.009 · DOI · Paper page
  27. Dvorak, 1986, Mast-cell degranulation in human hearts, N Engl J Med, 315, 969, 10.1056/NEJM198610093151515 · DOI
  28. Bennett, 2009, Bone marrow-derived mast cells accumulate in the central nervous system during inflammation but are dispensable for experimental autoimmune encephalomyelitis pathogenesis, J Immunol, 182, 5507, 10.4049/jimmunol.0801485 · DOI · Paper page
  29. Fukuda, 2009, Critical role of IgE-dependent mast cell activation in a murine model of allergic conjunctivitis, J Allergy Clin Immunol, 124, 827, 10.1016/j.jaci.2009.06.012 · doi:10.1016/j.jaci.2009.06.012
  30. Kneilling, 2007, Targeted mast cell silencing protects against joint destruction and angiogenesis in experimental arthritis in mice, Arthritis Rheum, 56, 1806, 10.1002/art.22602 · DOI
  31. Kaartinen, 1996, Mast cells in rupture-prone areas of human coronary atheromas produce and store TNF-alpha, Circulation, 94, 2787, 10.1161/01.CIR.94.11.2787 · DOI · Paper page
  32. Hara, 2002, Evidence for a role of mast cells in the evolution to congestive heart failure, J Exp Med, 195, 375, 10.1084/jem.20002036 · DOI · Paper page
  33. Ihara, 1999, Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta, Hypertension, 33, 1399, 10.1161/01.HYP.33.6.1399 · DOI · Paper page
  34. Tsuruda, 2006, Adrenomedullin in mast cells of abdominal aortic aneurysm, Cardiovasc Res, 70, 158, 10.1016/j.cardiores.2006.02.003 · DOI
  35. Sun, 2007, Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice, J Clin Invest, 117, 3359, 10.1172/JCI31311 · DOI · Paper page
  36. Vague, 1956, The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease, Am J Clin Nutr, 4, 20, 10.1093/ajcn/4.1.20 · DOI · Paper page
  37. Reaven, 1988, Banting lecture 1988. Role of insulin resistance in human disease, Diabetes, 37, 1595, 10.2337/diab.37.12.1595 · DOI · Paper page
  38. Groop, 2000, Genetics of the metabolic syndrome, Br J Nutr, 83, S39, 10.1017/S0007114500000945 · DOI · Paper page
  39. Zimmet, 1999, Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players, Ann NY Acad Sci, 892, 25, 10.1111/j.1749-6632.1999.tb07783.x · DOI · Paper page
  40. Xu, 2003, Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance, J Clin Invest, 112, 1821, 10.1172/JCI200319451 · DOI · Paper page
  41. Weisberg, 2003, Obesity is associated with macrophage accumulation in adipose tissue, J Clin Invest, 112, 1796, 10.1172/JCI200319246 · DOI · Paper page
  42. Wu, 2007, T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity, Circulation, 115, 1029, 10.1161/CIRCULATIONAHA.106.638379 · DOI · Paper page
  43. Miller, 2006, Cytokine production of CD8+ immune T cells but not of CD4+ T cells from Toxoplasma gondii-infected mice is polarized to a type 1 response following stimulation with tachyzoite-infected macrophages, J Interferon Cytokine Res, 26, 787, 10.1089/jir.2006.26.787 · DOI
  44. Sakaguchi, 2006, Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease, Immunol Rev, 212, 8, 10.1111/j.0105-2896.2006.00427.x · DOI · Paper page
  45. Sun, 2009, Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation, Circulation, 120, 973, 10.1161/CIRCULATIONAHA.109.849679 · DOI · Paper page
  46. Mallen-St Clair, 2006, Cathepsins L and S are not required for activation of dipeptidyl peptidase I (cathepsin C) in mice, Biol Chem, 387, 1143, 10.1515/BC.2006.141 · DOI
  47. Wang, 2006, Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors, J Biol Chem, 281, 6020, 10.1074/jbc.M509134200 · DOI · Paper page
  48. Shi, 2003, Deficiency of the cysteine protease cathepsin S impairs microvessel growth, Circ Res, 92, 493, 10.1161/01.RES.0000060485.20318.96 · DOI · Paper page
  49. Hotamisligil, 2006, Inflammation and metabolic disorders, Nature, 444, 860, 10.1038/nature05485 · DOI · Paper page
  50. Hotamisligil, 1993, Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance, Science, 259, 87, 10.1126/science.7678183 · DOI · Paper page
  51. Feinstein, 1993, Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates, J Biol Chem, 268, 26055, 10.1016/S0021-9258(19)74276-8 · DOI · Paper page
  52. Uysal, 1998, Functional analysis of tumor necrosis factor (TNF) receptors in TNF-alpha-mediated insulin resistance in genetic obesity, Endocrinology, 139, 4832, 10.1210/endo.139.12.6337 · DOI · Paper page
  53. Moller, 2000, Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes, Trends Endocrinol Metab, 11, 212, 10.1016/S1043-2760(00)00272-1 · DOI · Paper page
  54. Gonzalez-Gay, 2006, Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis, Clin Exp Rheumatol, 24, 83
  55. Kiortsis, 2005, Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis, Ann Rheum Dis, 64, 765, 10.1136/ard.2004.026534 · DOI · Paper page
  56. Hrnciar, 1999, Relation between cytokines (TNF-alpha, IL-1 and 6) and homocysteine in android obesity and the phenomenon of insulin resistance syndromes, Vnitr Lék, 45, 11
  57. Fried, 1998, Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid, J Clin Endocrinol Metab, 83, 847
  58. Amrani, 1996, Interleukin-1 effect on glycemia in the non-obese diabetic mouse at the pre-diabetic stage, J Endocrinol, 148, 139, 10.1677/joe.0.1480139 · DOI · Paper page
  59. Balakumar, 2009, Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions, Pharmacol Res, 60, 24, 10.1016/j.phrs.2009.02.002 · DOI
  60. Balakumar, 2009, Do resident renal mast cells play a role in the pathogenesis of diabetic nephropathy?, Mol Cell Biochem, 330, 187, 10.1007/s11010-009-0132-3 · DOI
  61. Kanwar, 2008, Diabetic nephropathy: mechanisms of renal disease progression, Exp Biol Med Maywood, 233, 4, 10.3181/0705-MR-134 · DOI · Paper page
  62. Jones, 2003, Mast cell infiltration and chemokine expression in progressive renal disease, Kidney Int, 64, 906, 10.1046/j.1523-1755.2003.00183.x · DOI · Paper page
  63. Okon, 2007, Increased mast cell density in renal interstitium is correlated with relative interstitial volume, serum creatinine and urea especially in diabetic nephropathy but also in primary glomerulonephritis, Pol J Pathol, 58, 193
  64. Ruger, 1996, Mast cells and type VIII collagen in human diabetic nephropathy, Diabetologia, 39, 1215, 10.1007/BF02658509 · DOI
  65. Sharma, 1993, The transforming growth factor-beta system and the kidney, Semin Nephrol, 13, 116
  66. Kondo, 2001, Role of mast cell tryptase in renal interstitial fibrosis, J Am Soc Nephrol, 12, 1668, 10.1681/ASN.V1281668 · DOI · Paper page
  67. Lindstedt, 2001, Activation of paracrine TGF-beta1 signaling upon stimulation and degranulation of rat serosal mast cells: a novel function for chymase, FASEB J, 15, 1377, 10.1096/fj.00-0273com · DOI · Paper page
  68. Weber, 1991, Pathological hypertrophy and cardiac interstitium. Fibrosis and renin–angiotensin–aldosterone system, Circulation, 83, 1849, 10.1161/01.CIR.83.6.1849 · DOI · Paper page
  69. Nicoletti, 1995, Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone, Hypertension, 26, 101, 10.1161/01.HYP.26.1.101 · DOI
  70. Hinglais, 1994, Colocalization of myocardial fibrosis and inflammatory cells in rats, Lab Invest, 70, 286
  71. Nicoletti, 1996, Inflammatory cells and myocardial fibrosis: spatial and temporal distribution in renovascular hypertensive rats, Cardiovasc Res, 32, 1096, 10.1016/S0008-6363(96)00158-7 · doi:10.1016/s0008-6363(96)00158-7
  72. Kuwahara, 2002, Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats, Circulation, 106, 130, 10.1161/01.CIR.0000020689.12472.E0 · DOI · Paper page
  73. Kuwahara, 2004, Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation?, Hypertension, 43, 739, 10.1161/01.HYP.0000118584.33350.7d · DOI · Paper page
  74. Kagitani, 2004, Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats, J Hypertens, 22, 1007, 10.1097/00004872-200405000-00024 · doi:10.1097/00004872-200405000-00024
  75. Olivetti, 1989, Long-term pressure-induced cardiac hypertrophy: capillary and mast cell proliferation, Am J Physiol, 257, H1766
  76. Rakusan, 1985, Protamine inhibits capillary formation in growing rat hearts, Circ Res, 57, 393, 10.1161/01.RES.57.3.393 · DOI
  77. Azizkhan, 1980, Mast cell heparin stimulates migration of capillary endothelial cells in vitro, J Exp Med, 152, 931, 10.1084/jem.152.4.931 · DOI · Paper page
  78. Shiota, 2003, A role for cardiac mast cells in the pathogenesis of hypertensive heart disease, J Hypertens, 21, 1935, 10.1097/00004872-200310000-00022 · DOI
  79. Panizo, 1995, Are mast cells involved in hypertensive heart disease?, J Hypertens, 13, 1201, 10.1097/00004872-199510000-00015 · DOI
  80. Levick, 2009, Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart, Hypertension, 53, 1041, 10.1161/HYPERTENSIONAHA.108.123158 · DOI · Paper page
  81. Lee, 1992, Mast cell-mediated inhibition of reverse cholesterol transport, Arterioscler Thromb, 12, 1329, 10.1161/01.ATV.12.11.1329 · DOI
  82. Kokkonen, 1987, Stimulation of mast cells leads to cholesterol accumulation in macrophages in vitro by a mast cell granule-mediated uptake of low density lipoprotein, Proc Natl Acad Sci USA, 84, 2287, 10.1073/pnas.84.8.2287 · DOI
  83. Kokkonen, 1987, Low-density-lipoprotein binding by mast-cell granules. Demonstration of binding of apolipoprotein B to heparin proteoglycan of exocytosed granules, Biochem J, 241, 583, 10.1042/bj2410583 · DOI
  84. Kokkonen, 1989, Stimulation of rat peritoneal mast cells enhances uptake of low density lipoproteins by rat peritoneal macrophages in vivo, Atherosclerosis, 79, 213, 10.1016/0021-9150(89)90126-3 · DOI
  85. Ma, 2000, Inhibition of mast cell-dependent conversion of cultured macrophages into foam cells with antiallergic drugs, Arterioscler Thromb Vasc Biol, 20, E134, 10.1161/01.ATV.20.12.e134 · DOI
  86. Ma, 1995, IgE-dependent generation of foam cells: an immune mechanism involving degranulation of sensitized mast cells with resultant uptake of LDL by macrophages, Arterioscler Thromb Vasc Biol, 15, 811, 10.1161/01.ATV.15.6.811 · DOI
  87. Lee, 2003, Apolipoprotein composition and particle size affect HDL degradation by chymase: effect on cellular cholesterol efflux, J Lipid Res, 44, 539, 10.1194/jlr.M200420-JLR200 · doi:10.1194/jlr.m200420-jlr200
  88. Heikkila, 2010, Mast cells promote atherosclerosis by inducing both an atherogenic lipid profile and vascular inflammation, J Cell Biochem, 109, 615, 10.1002/jcb.22443 · DOI

Cited by

See all 104

Metadata

Authors
Zhang, J., & Shi, G.-P.
Venue
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Publisher
Elsevier BV
Published
2012-01
Volume
1822
Issue
1
Pages
14-20
ISSN
0925-4439 (ISSN-L)
OpenAlex
W1984268475
Cited by
104
References
10
FWCI
2.69
Type
journal article
Language
en
Open access
bronze
Licence
Funders
  • NIH (HL60942, HL81090, HL88547)
  • American Heart Association Established Investigator Award (0840118N)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.